Providers

Data are scarce on the impact that breast cancer among mothers has on their children and their emotional development due to parenting stress and maternal depression.

A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.

Early CT screening leads to a 20-year lung cancer survival rate of 81%.

Managing toxicities for patients on immunotherapy requires collaboration with specialists to manage specific organ toxicities and moving beyond steroids, according to a presentation at the ESMO Congress 2023.

A network meta-analysis confirmed the efficacy of methotrexate for patients with rheumatoid arthritis (RA) and validated it as the primary reference conventional synthetic disease-modifying antirheumatic drug for treatment in this population.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the impacts of immunotherapy on outcomes for certain patients with non–small cell lung cancer.

A retrospective analysis reveals that pregnant patients with autoimmune skin diseases have higher risks for adverse pregnancy outcomes.

A cohort study of 65 clinical trials in multiple myeloma found that toxic effects are often described with subjective terminology that may not reflect adverse event rates reported in the studies.

Researchers concluded there is a clinically important increase in infection risk among patients with T1D in both primary care and hospital settings, and that guidelines must be developed to reflect this risk and encourage earlier treatment.

In a real-world, prospective study, upadacitinib demonstrated great potential for the treatment of rheumatoid arthritis (RA) regardless of a patient’s baseline C-reactive protein (CRP) levels.

Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.

The recent availability of 3 FDA-approved treatments for patients with spinal muscular atrophy (SMA) has dramatically altered patient outcomes and provided a wealth of new avenues for SMA research.

In a single-center, retrospective analysis, echocardiography demonstrated low sensitivity but high specificity for diagnosing pulmonary hypertension (PH) in advanced chronic obstructive pulmonary disease (COPD).

Patients with diverse skin types can experience diagnostic delays, access to care issues, and quality-of-life burdens that a navigator program may be able to help alleviate.

To stress the importance of considering pulmonary complications in sickle cell disease (SCD), researchers compiled an overview on the state of research and available treatment options for patients with SCD associated with pulmonary hypertension.

The study also identified similar 12-month outcomes between torsemide and furosemide regardless of heart failure (HF) type.

Alexander Fay, MD, PhD, joined for a Q&A about the current state of spinal muscular atrophy (SMA) treatment and the unanswered questions in the field.

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in American College of Rheumatology-20 (ACR20), ACR50, and Disease Activity Score in 28 joints with Erythrocyte Sedimentation Rate responses.

A study from investigators in Italy sheds further light on the relationship between physical activity and diabetic polyneuropathy risk in patients with type 1 diabetes.

The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.

A recent review aimed to characterize the relationship between tumor burden and clinical outcomes in patients treated with chimeric antigen receptor (CAR) T-cell therapy, highlighting the potential mechanisms of high tumor burden impacting CAR T-cell failure.

A retrospective, exploratory analysis identifies biomarkers predictive of spinal muscular atrophy (SMA) response to nusinersen and suggests the efficacy of using machine learning algorithms to anticipate patient outcomes.

In a recent study, reducing dietary sodium demonstrated a blood pressure–reducing effect similar to that of a commonly used first-line antihypertensive medication.

Alyson Moadel-Robblee, PhD, deputy director of community engagement and cancer health equity at Montefiore Einstein Comprehensive Cancer Center, discussed the center's evolving patient distress screening process and the Bronx Oncology Living Daily support program for patients with cancer.

A Biologics License Application has been submitted to the FDA review for sotatercept in the treatment of pulmonary arterial hypertension.

The study findings provide the first in-depth look at the relationship between chromosomal changes in tumor cells and immune components of the tumor microenvironment.

The FDA has approved pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

The tool assesses the risk of heart attack, stroke, and, for the first time, heart failure, offering a more comprehensive perspective on cardiovascular health.

Michael Yim, MD, board-certified family physician, discussed the need for and logistics of collaboration between oncologists and primary care providers.

According to researchers, the most prevalent risk factors in children with type 1 spinal muscular atrophy (SMA) are hypercalciuria and elevated urine specific gravity.